Document is current

Article History

Received: 8 July 2024

Accepted: 24 February 2025

First Online: 28 February 2025

Declarations

:

: The authors declare no competing interests.

: All animal experiments were conducted in accordance with the ARRIVE Guidelines, the Guide for the Care and Use of Laboratory Animals (), and the Institutional Animal Care and Use Committee (IACUC) of Gempharmatech Co., Ltd., following approval by the Animal Ethics Committee (GPTAP20231109-6). To thoroughly consider the ethical implications of using fetal liver cells for transplantation, we evaluated several alternative methods before selecting fetal liver cells as the experimental material. While adult stem cells and other cell types can be used in some studies, fetal liver cells offer unique advantages in mimicking the pathophysiology of human α-thalassemia. Fetal liver cells contain a high number of hematopoietic stem cells, which more accurately reflect the disease state. The aim of this study is to develop a new mouse model to better understand the pathogenic mechanisms of α-thalassemia and provide a platform for future therapeutic strategies. This model will enable us to investigate the molecular mechanisms of the disease and test potential treatments, particularly gene therapy. We believe that the potential scientific and societal benefits of this research outweigh the ethical risks.